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SUPPLEMENTARY FILES 34 
Fig.S1. Differential DNA-methylated genes and PCA for FTD. (A) P-value distribution 35 
plot for the comparison FTD versus Control using Student T-test. (B) Volcano plot depicting 36 
genes with the fold-difference on the x-axis and -log10(P-value) on the y-axis. (C) Principal 37 
Component analysis on the top 20% probes with highest variance. 38 
Fig.S2. Differential DNA-methylated genes and PCA for FTD-ALS. (A) P-value 39 
distribution plot for the comparison FTD-ALS versus Control using Student T-test. (B) 40 
Volcano plot depicting genes with the fold-difference on the x-axis and -log10(P-value) on 41 
the y-axis.  42 
Fig.S3. GTEx tissue enrichment for the differential DNA-methylated genes in FTD-43 
ALS. Tissue enrichment was computed by following the approach as outlined in Fig.2A. (A) 44 
Tissue enrichment for FTD-ALS with the 25 GTEx specific tissues. (B) Brain tissue 45 
enrichment for FTD-ALS with the 13 GTEx specific brain tissues. Genes are colored with the 46 
tissue specific color. 47 
Fig.S4. Batch correction and differential DNA methylated genes after extending control 48 
data set. (A) batch effect of samples without correction. (B) Clustering of samples after 49 
batch-effect correction. (C) Differential DNA methylated probes for Controls (this study) vs. 50 
Non-smokers. (D) Differential DNA methylated probes for FTD vs. Non-smokers. 51 
Fig.S5. Venn diagram depicting overlap of genes from the original meta-analysis. Genes 52 
from the meta-analysis from the original study were gathered and overlaid with the 53 
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Table S1
Id P Location Mutation type CADD score Min(P) Id P BH Location T-stat Hyper/hypo Phenotype Wikigene
ELP2/ SLC39A6 chr18 . rs16967474 0.03221 exonic nonsynonymous SNV 25.3 0.03221 cg12339809 0.0486004 Island -5.0795263 Hypomethylation . . Yes
ZMIZ1 chr10 . rs12571751 0.03573 intronic . . 0.03573 cg19168578 0.0486004 Island -4.9091067 Hypomethylation . .
AP3M1 chr10 - exm954373 0.01207 intronic . . 0.01207 cg04760117 0.0486004 . 4.9137135 Hypermethylation . adaptor-related protein complex 3, mu 1 subunit
ZNF808,ZNF701 chr19 + exm2216491 0.02767 intergenic . . 0.02767 cg10782349 0.0489753 Island 4.9227971 Hypermethylation . zinc finger protein 701
TPK1 chr7 - . . . . . . cg16316507 0.0486004 Island -4.9587098 Hypomethylation
THIAMINE METABOLISM 
DYSFUNCTION SYNDROME 5 
thiamin pyrophosphokinase 1
STK39 chr2 - . . . . . . cg03159329 0.0486004 Island -4.9394391 Hypomethylation . serine threonine kinase 39
BMS1P4 chr10 - . . . . . . cg26771998 0.0489753 Island -4.8163424 Hypomethylation . BMS1 pseudogene 4
NCRNA00188;SNORD49A;SNORD49Bchr17 . . . . . . . cg02830903 0.0489753 Island -4.8184838 Hypomethylation . .
LRRC8D chr1 + . . . . . . cg01533966 0.0486004 . 4.9315597 Hypermethylation . leucine rich repeat containing 8 family, member D






Id P Location Mutation type CADD score min(P ) for gene Id P BY Location Tstat
PCDHA4 chr5 rs59233330 1.92E-04 exonic nonsynonymous SNV 0 1.92E-04 cg02357321 3.348E-02 N_Shore -6.43
DLG1 chr3 - rs74674649 6.01E-04 exonic nonsynonymous SNV 28 6.01E-04 cg12594803 2.879E-02 . -7.04 Yes
KIAA1147 chr7 - rs201876806 9.13E-04 exonic nonsynonymous SNV 23 9.13E-04 cg24662653 2.890E-03 Island -6.51 Yes
HPS6 chr10 + rs36078476 1.07E-03 exonic nonsynonymous SNV 0 1.07E-03 cg02840794 3.383E-03 Island -7.36
GPN3 chr12 rs143166802 1.69E-03 exonic nonsynonymous SNV 2 1.69E-03 cg00558990 1.524E-02 N_Shore -5.99
GGA1 chr22 + rs143909159 2.91E-03 exonic nonsynonymous SNV 34 2.91E-03 cg21268578 2.796E-02 . -7.16
PTPRN2 chr7 - rs142437536 3.02E-03 exonic nonsynonymous SNV 0 3.02E-03 cg05135176 7.528E-03 S_Shore -5.52 Yes
PPP1R36,PLEKHG3 chr14 + rs117300689 3.29E-03 intergenic . . 3.29E-03 cg26763365 4.418E-02 Island -5.55
MRPL21 chr11 rs200690672 3.96E-03 exonic nonsynonymous SNV 9 3.96E-03 cg26065952 2.314E-02 N_Shore -5.70 Yes
IGHMBP2 chr11 rs201692151 4.00E-03 exonic nonsynonymous SNV 23 4.00E-03 cg26065952 2.314E-02 N_Shore -5.70 Yes
MTRF1 chr13 - rs9532758 5.25E-03 exonic nonsynonymous SNV 7 5.25E-03 cg21446692 6.388E+08 . -10.38
ASPM chr1 - rs150125249 5.78E-03 exonic nonsynonymous SNV 34 5.78E-03 cg11336294 2.729E-02 . -5.59
NEDD9 chr6 - rs112742585 5.85E-03 exonic nonsynonymous SNV 13 5.85E-03 cg05917225 9.185E-03 . -5.79
PRSS36 chr16 - rs145749002 6.04E-03 exonic nonsynonymous SNV 33 6.04E-03 cg14301190 4.949E-03 Island -6.68
PPP1R36,PLEKHG3 chr14 + rs117434243 6.48E-03 intergenic . . 3.29E-03 cg26763365 4.418E-02 Island -5.55
IGHMBP2 chr11 rs622082 7.05E-03 exonic nonsynonymous SNV 0 4.00E-03 cg26065952 2.314E-02 N_Shore -5.70 Yes
PKNOX1 chr21 + rs2839627 8.18E-03 intronic . . 8.18E-03 cg04193427 4.013E-02 Island -5.38 Yes
CNKSR1 chr1 + rs144396219 8.32E-03 exonic nonsynonymous SNV 28 8.32E-03 cg09890400 1.962E-02 . -8.83 Yes
UBTD2 chr5 - rs17074452 9.54E-03 exonic nonsynonymous SNV 18 9.54E-03 ch.5.3268483F 4.949E-03 . -5.84 Yes
GGA1 chr22 + rs138525343 9.76E-03 exonic nonsynonymous SNV 27 2.91E-03 cg21268578 2.796E-02 . -7.16
IGHMBP2 chr11 rs145226920 0.01001 exonic stopgain 35 4.00E-03 cg26065952 2.314E-02 N_Shore -5.70 Yes
FAH chr15 + rs144234072 1.07E-02 exonic nonsynonymous SNV 27 0.01066 cg06856840 1.648E-02 . -6.95
RBM14 chr11 + rs148119991 1.28E-02 exonic nonsynonymous SNV 5 0.01281 cg03249986 1.005E-02 Island -5.46
NEDD9 chr6 - rs34044517 1.63E-02 exonic nonsynonymous SNV 24 5.85E-03 cg05917225 9.185E-03 . -5.79
FAH chr15 + rs34749737 0.01663 exonic nonsynonymous SNV 6 0.01066 cg06856840 1.648E-02 . -6.95
BPHL chr6 + rs2231365 0.01671 splicing . 24 0.01671 cg22799902 6.218E-03 Island -6.43
ARHGAP10 chr4 + rs144604709 0.0183 exonic nonsynonymous SNV 0 0.0183 ch.4.2714611R 2.836E-02 . -4.78
ACTN3 chr11 rs201576110 0.02133 exonic nonsynonymous SNV 32 0.02133 cg25117505 6.388E+08 Island -8.39
FGD6 chr12 rs143773760 0.02322 exonic nonsynonymous SNV 9 0.02322 cg02688710 2.339E-02 Island -6.09 Yes
WDR66 chr12 + rs77422261 0.02336 exonic nonsynonymous SNV 30 0.02336 cg21016266 1.331E-02 Island -4.89
RBM47 chr4 - rs1688939 0.02571 intronic . . 0.02571 cg00802478 4.080E-02 . -5.98 Yes
IQSEC1 chr3 - rs144790333 0.02763 exonic nonsynonymous SNV 23 0.02763 cg02559896 6.666E-03 Island -5.14
DLG1 chr3 - rs141544348 0.03024 exonic nonsynonymous SNV 35 6.01E-04 cg12594803 2.879E-02 . -7.04 Yes
DUOX1 chr15 rs143304688 0.03047 exonic stopgain 44 0.03047 cg10496082 1.526E-04 Island -6.61
RTDR1 chr22 rs3788337 0.03193 intronic . . 0.03193 cg21100191 3.904E-02 Island -5.23
CCR5,CCRL2 chr3 + . 0.03194 intergenic . . 0.03194 cg10952220 1.002E-02 . -7.39
CCRL2 chr3 + . 0.03355 downstream . . 0.03194 cg10952220 1.002E-02 . -7.39
PCDHA3 chr5 rs146951816 0.0354 exonic nonsynonymous SNV 15 0.0354 cg02357321 3.348E-02 N_Shore -6.43
PARP11,CCND2 chr12 + rs11063069 0.03845 intergenic . . 0.01055 cg05987650 8.273E-03 Island -6.49
C6orf70 chr6 rs140632188 0.04056 exonic nonsynonymous SNV 23 0.04056 cg22807378 1.211E-02 Island -7.15
IGHMBP2 chr11 rs17612126 0.04126 exonic nonsynonymous SNV 1 4.00E-03 cg26065952 2.314E-02 N_Shore -5.70 Yes
TCTE3 chr6 rs116980543 0.04138 exonic nonsynonymous SNV 10 0.04138 cg22807378 1.211E-02 Island -7.15
HERV-Fb1,PKNOX1 chr21 + . 0.04328 intergenic . . 8.18E-03 cg04193427 4.013E-02 Island -5.38
FGFR4 chr5 + . 0.04391 exonic synonymous SNV . 0.04391 cg21042539 4.943E-02 Island -5.63
CLRN2 chr4 + rs201124485 0.04711 exonic nonsynonymous SNV 21 0.04711 cg16760587 1.143E-03 S_Shelf -6.06
COL15A1 chr9 + rs199906142 3.62E-03 exonic nonsynonymous SNV 23 0.003618 cg18115656 3.656E-02 Island 5.37
TNRC18 chr7 - rs112785272 6.27E-03 exonic nonsynonymous SNV 19 6.27E-03 cg10546562 1.010E-02 N_Shore 5.91
SLC26A7 chr8 + rs200788056 9.04E-03 exonic nonsynonymous SNV 23 9.04E-03 cg25481252 2.582E-03 . 7.38
DOCK8 chr9 + rs77399114 9.95E-03 exonic nonsynonymous SNV 9 9.95E-03 cg13876553 2.938E-02 . 5.41
PCNX chr14 + rs200261097 0.01309 exonic nonsynonymous SNV 32 0.01309 cg10066683 4.218E-02 . 5.34 Yes
PRICKLE2,ADAMTS9 chr3 - rs7648640 0.01701 intergenic . . 0.01701 cg11044162 2.539E-02 N_Shore 4.75
WDR35 chr2 - rs148436608 0.02293 exonic nonsynonymous SNV 16 0.02293 cg13734338 2.796E-02 . 6.00 Yes
SLC1A5 chr19 - rs3027961 0.02329 exonic nonsynonymous SNV 7 0.02329 cg08533710 1.634E-02 S_Shore 5.00
ATXN7L1 chr7 - rs10435352 0.03096 intronic . . 0.03096 cg05424831 3.142E-03 . 5.46
MEGF6 chr1 - rs61910697 0.03109 exonic nonsynonymous SNV 20 0.03109 cg04391135 3.451E-03 Island 6.21
DOCK8 chr9 + rs12347078 0.03557 intronic . . 9.95E-03 cg13876553 2.938E-02 . 5.41
PCNX chr14 + rs151313378 0.03622 exonic nonsynonymous SNV 15 0.01309 cg10066683 4.218E-02 . 5.34 Yes
MEGF6 chr1 - rs12075570 0.0367 exonic nonsynonymous SNV 9 0.03109 cg04391135 3.451E-03 Island 6.21
AGAP1 chr2 + rs2292708 0.03677 exonic synonymous SNV . 0.03677 cg00834223 4.423E-03 . 6.19
ARHGAP8,PRR5-ARHGAP8chr22 + rs55849456 0.03933 exonic nonsynonymous SNV 25 0.03933 cg06647930 4.418E-02 S_Shelf 4.26 Yes
C1orf94 chr1 + rs61741807 0.04033 exonic nonsynonymous SNV 0 0.04033 cg15098077 1.363E-04 N_Shore 7.96
PBX1,LMX1A chr1 + . 0.04041 intergenic . . 0.04041 cg20682146 4.200E-02 Island 6.22
COL1A2 chr7 + . 0.04129 exonic synonymous SNV . 0.04129 cg12563520 3.706E-02 . 6.05
HS6ST3 chr13 + rs4771948 0.04256 intronic . . 0.04256 cg09122588 4.527E-02 . 5.11
ARHGAP8,PRR5-ARHGAP8chr22 + rs16992915 0.04662 exonic nonsynonymous SNV 19 0.03933 cg06647930 4.418E-02 S_Shelf 4.26 Yes
ESYT2 chr7 - rs2305475 0.04728 exonic nonsynonymous SNV 23 0.04728 cg19584649 9.356E+09 . 6.66 Yes
AHRR chr5 + rs201569850 0.04754 exonic nonsynonymous SNV 12 0.04754 cg16577724 3.796E-02 . 5.86 Yes
ESYT2 chr7 - rs2305473 0.04755 exonic nonsynonymous SNV 14 0.04728 cg19584649 9.356E+09 . 6.66 Yes






Id P Location Mutation type CADD score min(P ) for gene Id P BY Location Tstat
AP3M1 chr21 0.0121 intronic 0.0121 cg04760117 0.0486004 NaN 4.913713
ZMIZ1/LOC283050 chr11 rs12571751 0.0357 intronic 0.0357 cg19168578 0.0486004 Island -4.90911






Gene-symbol Degree Gene-symbol Degree Gene-symbol Degree Gene-symbol Degree
THRAP3 33 MDGA1 11 PACS2 4 COL15A1 0
C5orf45 33 SLC1A5 11 DUOX1 4 FRMD4A 0
ANKRD17 32 B3GALT6 10 EVI5L 4 MRPL21 0
ATXN7L1 32 C2orf63 10 PPP1R8 3 TSKU 0
GPR176 32 DOCK8 10 FYN 3 PTGER2 0
IGHMBP2 31 DCLK1 10 TATDN1 3 MPV17L 0
PCNX 31 LSM14A 10 UBE2D1 3
ADAR 30 RBM47 9 WDR66 3
GAK 30 CAMLG 9 PLEKHG3 3
ZNF544 30 SSH3 9 TMC7 3
BOP1 29 CMIP 9 DYNLL2 3
RTN1 29 PALLD 8 SIGLEC5 3
POLR2A 29 FAM35A 8 RABGGTB 2
SSTR2 29 CLEC2B 8 CCNYL1 2
TNRC18 28 VEZT 8 CMTM7 2
PKNOX1 28 GPN3 8 AADAT 2
SDF4 27 BTBD3 8 BPHL 2
RAB1A 26 BCAR3 7 NEDD9 2
TRIM23 26 ITPKB 7 KIAA1147 2
UNC45A 26 RPIA 7 RPS13 2
GNL3 24 LY96 7 PTPRJ 2
DIP2C 24 GLUD1 7 FAH 2
ARHGEF3 23 NINJ2 7 RNF220 1
PBRM1 22 METTL7A 7 NOL10 1
ERC1 22 TFDP1 7 LMAN2 1
RFWD3 22 ZNF444 7 GMNN 1
UNK 22 CCRL2 6 C6orf70 1
TGOLN2 21 ADAMTS9 6 COL1A2 1
GGA1 21 DLG1 6 KIAA1274 1
PTP4A2 20 FGD4 6 POLR2G 1
ACTR10 18 SAP18 6 RASSF8 1
FAM110B 17 JMJD6 6 PRSS36 1
IQSEC1 16 PIK3R3 5 AATF 1
FAM50B 16 PBX1 5 MEGF6 0
ESYT2 15 LRRC2 5 DNALI1 0
RBM14 15 EHHADH 5 GSTM1 0
RAB6A 15 FGFR4 5 OLFML2B 0
HPS6 14 WIPF3 5 WDR35 0
GSDMD 13 CDKN1C 5 AGAP1 0
MTRF1 13 C12orf29 5 ARHGAP10 0
HP1BP3 12 HAR1A 5 SAP30 0
C5orf44 12 AKIRIN1 4 ARL15 0
UBTD2 12 NPY1R 4 PEX7 0
FUCA2 12 AHRR 4 TCTE3 0
PTPRN2 12 RNASEH2C 4 ABHD11 0
MAP3K8 12 ZDHHC24 4 HSPB1 0
CNKSR1 11 CCND2 4 C8orf44 0
GRK6 11 FGD6 4 NDUFB9 0
lists continues (1) lists continues (2) lists continues (3)
Table S5
Gene-symbol GSE18632 GSE13162 GSE68605 GSE40438
Overlap with differential DNA-

























































































































1 GSE18632 4407 36 0.0276* 1 0.7666
2 GSE13162 2572 29 0.0445* 0 1
3 GSE68605 7 0 1 0 1
4 GSE40438 0 - - - -
4
PData set GEO accesion nr.
#Genes with 
P BH<0.05
#Genes in overlap 
with FTD-ALS




Daniela Galimberti et al, 2013 Russ, J. et al, 2012
GRN - (entire open reading frame) C9orf72 - (2KB upstream promoter region)
44060543-44061296 (CpG21) 43972053-44039685 (CpG27) 43971747-43972052 (CpG300) 43971748-44105699 27573864-27575864
Li, Y et al Mapt cg05533539 chr17 44104521-44104571
Li, Y et al Grn cg19107120 chr17 42430376-42430426
Li, Y et al Grn cg11999384 chr17 42422811-42422861
Li, Y et al Grn cg12837296 chr17 42426483-42426533
Li, Y et al Grn cg20679560 chr17 42423025-42423075
Li, Y et al Grn cg23570245 chr17 42426011-42426061
Li, Y et al Grn cg24420717 chr17 42426506-42426556
Li, Y et al Grn cg17714154 chr17 42422247-42422297
Li, Y et al Grn cg18872749 chr17 42421993-42422043
Li, Y et al Grn cg01146514 chr17 42422409-42422459
Li, Y et al Grn cg04269641 chr17 42422442-42422492
Li, Y et al Grn cg07777378 chr17 42422412-42422462
Li, Y et al Grn cg17101358 chr17 42422688-42422738
Li, Y et al C9orf72 cg13958452 chr9 27571484-27571534
Li, Y et al C9orf72 cg05990720 chr9 27573650-27573700
Li, Y et al C9orf72 cg11613875 chr9 27573889-27573939 X
Li, Y et al C9orf72 cg14363787 chr9 27573986-27574036 X
Data used in our study
Marie-Laure Caillet-Boudin et al, 2015
MAPT - extended CpG regions
Location (range)Genesymbol Probe id chr
Table S8
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